Combination of an insulin and a GLP-1 agonist
First Claim
Patent Images
1. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
- (a) insulin glargine or a pharmaceutically acceptable salt thereof, and(b) desPro36exendin-4(1-39)-Lys6-NH2 (AVE0010) or a pharmaceutically acceptable salt thereof;
wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 μ
g/mL; and
wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 μ
g and about 2 mg.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
-
Citations
8 Claims
-
1. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
-
(a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro36exendin-4(1-39)-Lys6-NH2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 μ
g/mL; andwherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 μ
g and about 2 mg. - View Dependent Claims (2, 3)
-
-
4. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
-
(a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro36exendin-4(1-39)-Lys6-NH2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 20 m/ml to about 150 μ
g/ml. - View Dependent Claims (5, 6)
-
-
7. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
-
(a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro36exendin-4(1-39)-Lys6-NH2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL, and wherein the ratio of insulin glargine and AVE0010 in the pharmaceutical formulation is about 1.5 units to about 4 units of insulin glargine to 1 μ
g of AVE0010. - View Dependent Claims (8)
-
Specification